Ah, the financial markets. A bastion of logic, predictability, and calm, right? Not when Donald J. Trump is in the news cycle, apparently. In recent days, the former (and potentially future) President has once again proven his unparalleled ability to inject a potent cocktail of excitement, confusion, and outright whiplash into the global economy. From groundbreaking drug deals to beef probes and international boycotts, the market’s reaction has been, shall we say, diverse. Let’s dive into the latest pronouncements and the ensuing financial fireworks, all delivered with the subtlety of a bull in a china shop.
The Art of the Deal (and the Dip)
Fresh off the presses, President Trump, ever the dealmaker, announced a landmark agreement with pharmaceutical giants Eli Lilly and Novo Nordisk to slash prices on their highly coveted GLP-1 weight-loss drugs. The deal, touted as a win for American consumers, promises significant reductions for Medicare, Medicaid, and even direct cash payers through the soon-to-be-launched “TrumpRx” platform, with prices potentially dropping from the dizzying heights of $500-$1,000 to a more palatable $149-$350 per month. And, in a classic Trumpian twist, the companies also secured a three-year exemption from tariffs.
One might expect such a consumer-friendly move to send pharmaceutical stocks soaring, or at least holding steady. But the market, much like a teenager, often reacts in unexpected ways. Shares of Novo Nordisk (NVO), the maker of Wegovy, promptly fell as much as 3% on Friday, November 7, 2025, after the deal was announced, settling down 1.8% by mid-morning GMT. Other reports noted NVO was down 3.7% at 1450 GMT, contributing to an overall drop of more than 8% for the stock since the previous Friday. Eli Lilly (LLY) also saw its shares slip on Friday. Analysts, ever the optimists, are calling it a “near-term headwind” that could lead to a “medium-to-long-term boost” due to increased volumes. Because nothing says “boost” like an immediate price cut and a stock dip, apparently.
Not content with addressing the nation’s waistlines, Trump also turned his attention to the very beef that might be contributing to them. He announced a Department of Justice probe into major meatpacking companies, accusing them of “Illicit Collusion, Price Fixing, and Price Manipulation” to drive up beef prices. Given that a mere four firms (Tyson Foods, Cargill, JBS, and National Beef Packing Company) control an estimated 80-85% of the U.S. beef processing market, the target is certainly concentrated. The market’s reaction was swift and, for some, painful. Shares of Brazil’s JBS N.V. (JBS) plummeted as much as 6.2% in after-hours trading on Friday, November 7, 2025, falling to $12.84. Tyson Foods (TSN) initially dropped by as much as 2% before staging a modest recovery. Meanwhile, cattle futures, perhaps sensing a shift in the food chain’s power dynamics, rallied, with live cattle futures advancing $2.50 to $3.05 and feeder cattle futures up $2.80 to $4.35 on Friday, November 8, 2025. It seems ranchers are finally getting some good news, even if it’s at the expense of corporate meat behemoths.
And let’s not forget the “Rare Earths Deal” with China, announced to “ease supply concerns.” While details remain sparse, the agreement supposedly involves China committing to a one-year rare-earth export deal and a reduction of tariffs on Chinese exports from 57% to 47%. One might assume that securing critical minerals and reducing tariffs would be a boon for the American rare earth sector. One would be wrong. U.S. rare earth stocks, defying all conventional wisdom, reportedly plummeted. MP Materials (MP) saw its stock down 9.2% in the week leading up to October 30, 2025, while other players like The Metals Company, Critical Metals, USA Rare Earth, and Trilogy Metals experienced declines ranging from 3.5% to a staggering 22.9%. Though, in a testament to the market’s short attention span, MP was later reported up +12.78% at $58.59 on November 7, 2025, with analysts still eyeing a $77.80 target. Because nothing says “stability” like a 20% swing on a critical minerals deal.
The Global Disruptor: Tariffs, Boycotts, and the VIX
Beyond domestic affairs, President Trump continues his global tour de force, keeping international markets on their toes. Canada, it seems, has once again found itself in the crosshairs, with Trump “threatening Canada with Economic Penalties in Trade Escalation” and imposing tariffs on Canadian goods earlier in 2025. [cite: user alert] While an analyst noted that agriculture trade between the U.S. and Canada remains “pretty much all tariff free,” the broader impact has been felt. The Canadian main stock index, the S&P/TSX Composite (TSX), dropped 72.89 points to 26,210.56 on Thursday, May 29, 2025, as investors grappled with court decisions surrounding Trump’s tariffs. Meanwhile, U.S. markets, perhaps enjoying Canada’s pain, actually rose on the same day.
China, of course, is a perennial favorite for Trump’s pronouncements. The latest gem? A threat to “start testing nuclear weapons.” [cite: user alert] While the direct market impact of such a statement is, thankfully, unquantifiable in traditional financial metrics, it certainly doesn’t foster an environment of serene investment. More tangibly, the Supreme Court’s hearing on Trump’s tariffs on Wednesday, November 5, 2025, contributed to a lower close for Wall Street. The Dow Jones Industrial Average (DJI) fell 0.5% (251.44 points), the Nasdaq Composite (IXIC) tumbled 2% (486.09 points), and the S&P 500 (SPX) slid 1.2%. This follows a pattern from earlier in 2025, when Trump’s April 2 “Liberation Day” announcement of extensive new tariff policies triggered a market selloff, marking the largest decline since 2020, with the S&P 500 experiencing a -12.1% intra-month drop. Conversely, a pause in tariff increases on April 9, 2025, sparked a historic rally, with the S&P 500 surging 9.52%, the Dow Jones 7.87%, and the Nasdaq an impressive 12.16% in a single day. The volatility index, or VIX, spiked to over 55 in April, the highest since COVID-19. Clearly, the market loves a good tariff drama, as long as it ends with a pause.
And for those keeping score on international diplomacy, Trump also announced a U.S. boycott of the G20 summit in South Africa, citing allegations of “white persecution.” [cite: user alert] While the immediate financial impact of this particular move is less clear, it certainly adds another layer of geopolitical intrigue to an already complex global landscape. Goldman Sachs analysts, looking ahead from November 2024, predicted that changes to U.S. trade policy could subtract 0.4% from global GDP, with a 10% across-the-board tariff potentially tripling that impact. They also sagely noted that tariffs are “largely passed on to consumer prices.” So, while the rhetoric might be free, the consumer will likely pay the bill.
Truth Social and the Trillion-Dollar Question
No analysis of Trump’s market impact would be complete without a nod to his preferred digital soapbox, Truth Social. It was there, for instance, that he proposed a “radical healthcare shake-up” and praised Vivek Ramaswamy. [cite: user alert] More dramatically, a November 1st post on Truth Social regarding Christianity was reportedly linked to “massive sell-offs” and “N2.8 Trillion in Losses” in the Nigerian stock market. [cite: user alert] While the direct causal link and the exact magnitude of such a loss specifically to that post are difficult to verify with available data, it highlights the outsized influence of Trump’s pronouncements, even on seemingly unrelated global markets. The stock of his own company, Digital World Acquisition Corp. (DJT), which merged with Truth Social, remains a bellwether for his political fortunes, though specific recent movements tied to these alerts are not readily available.
Analysts, in their perpetual quest for clarity, continue to grapple with the “Trump factor.” As of January 2025, Oakglen Wealth maintained a positive outlook for equities in 2025, assuming Trump could reduce regulation and lower taxes “without creating significant disruptions through tariffs.” Goldman Sachs, in November 2024, projected the S&P 500 to climb 9% to 6300 in the next 12 months, driven by “robust earnings growth,” but acknowledged that “beneath the surface, however, the outlook has changed substantially for some sectors” due to policy uncertainty, especially tariffs. The consensus seems to be that volatility will likely remain high in 2025, with “equity markets priced to perfection” leaving little room for error. And, in a final ironic twist, the “America First” market vibe seems to have faded, with international stocks actually outperforming U.S. equities over the past year (as of October 2025). Perhaps the market, much like a seasoned investor, has learned to diversify its emotional portfolio.
So, there you have it. Another week, another flurry of announcements, and another unpredictable dance between policy, personality, and profit. From obesity drugs to beef prices and global trade skirmishes, the Trump effect on markets remains as undeniable as it is bewildering. Investors, buckle up; the ride is far from over.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.